Melanoma | Topics

 
FDA Approves FoundationOne CDx as Companion Diagnostic for BRAF Inhibitor Regimens in Melanoma
December 08, 2021

FoundationOne CDx has been approved by the FDA as a companion diagnostic for patients with melanoma undergoing treatment with a BRAF inhibitor.

FDA Approves Adjuvant Pembrolizumab for the Treatment of Stage IIB/IIC Melanoma
December 04, 2021

Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IIB or IIC melanoma.

Nivolumab/Ipilimumab +/- Dabrafenib and Trametinib Improved Survival for BRAF+ Metastatic Melanoma
November 17, 2021

Phase 3 data indicated that the combination of nivolumab and ipilimumab followed by treatment with dabrafenib and trametinib, if necessary, resulted in greater overall survival at 2 years for patients with treatment-naïve BRAF-mutant metastatic melanoma.

Lifileucel Plus Pembrolizumab Yields Positive ORR in Advanced Cancers
November 16, 2021

Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.

First-Line Nivolumab/Ipilimumab Garners Durable Responses in Asymptomatic Melanoma Brain Metastases
November 12, 2021

Patients with melanoma who have asymptomatic brain metastases had long-lasting responses after being treated with first-line nivolumab and ipilimumab.

Future Promise for Advanced Melanoma Seen With Lifileucel TIL Therapy
November 04, 2021

Lifileucel, a tumor infiltrating therapy, could be the best treatment for heavily pretreated patients with advanced melanoma, with investigators at Atlantic Health System examining this treatment modality in clinical trials.

UV1 Cancer Vaccine Receives FDA Fast Track Designation in Melanoma
November 03, 2021

UV1 has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.

Duration of Treatment for Melanoma
November 02, 2021

John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.

Taking Drug Holidays Amidst Melanoma Therapy
November 02, 2021

Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.

Using ctDNA to Monitor Patients With Melanoma
October 26, 2021

An expert in melanoma cancer treatment examines monitoring patients with melanoma using ctDNA.